Allogene Q4 net loss $38.8M; cash runway into Q1 2028; cema-cel ALPHA3 interim April 2026

Allogene Therapeutics, Inc.

Q4 net loss $38.8M ($0.17/share); FY 2025 net loss $190.9M ($0.87/share).
Cash, equivalents, investments $258.3M; runway extended into Q1 2028 via disciplined spending, $23.7M escrow return.
Pivotal Phase 2 ALPHA3 trial of cema-cel in 1L LBCL; interim futility analysis (MRD clearance, safety) planned April 2026.
Phase 1 RESOLUTION trial of ALLO-329 (CD19/CD70 CAR T) in autoimmune diseases; proof-of-concept data expected June 2026.
ALLO-316 TRAVERSE trial in RCC completed Phase 1b enrollment; exploring partnering opportunities.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Allogene Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $190.9 million, EPS $0.87 per share.

Period: the year ended December 31, 2025
Net income: $190.9 million
EPS: $0.87 per share
Result: reported results

Exact text from the filing

For the full year of 2025, net loss was $190.9 million, or $0.87 per share, including non-cash stock-based compensation expense of $37.6 million and non-cash impairment of long-lived asset expense of $2.4 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Allogene Therapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income $38.8 million, EPS $0.17 per share.

Period: the fourth quarter ended December 31, 2025
Net income: $38.8 million
EPS: $0.17 per share
Result: reported results

Exact text from the filing

Net loss for the fourth quarter of 2025 was $38.8 million, or $0.17 per share, including non-cash stock-based compensation expense of $8.1 million.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-017230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.